新的药物组合显示,慢性淋巴细胞白血病病人的存活率有所提高。 New drug combinations show improved survival rates for chronic lymphocytic leukemia patients.

在ASH年会上的一项研究表明,在未经治疗的慢性淋巴细胞白血病患者中,acalabrutinib和venetoclax的组合,与或没有obinutuzumab,改善了无进展的生存率. A study at the ASH Annual Meeting showed that a combination of acalabrutinib and venetoclax, with or without obinutuzumab, improved progression-free survival in patients with untreated chronic lymphocytic leukemia. 36个月的逐步无损存活率为综合疗法83.1%和76.5%,而标准治疗为66.5%。 The 36-month progression-free survival rates were 83.1% and 76.5% for the combination therapies versus 66.5% for standard treatment. 研究表明,这些新的疗法可以成为一种固定期限的治疗选择,并取得更好的结果。 The study suggests these new therapies could become a fixed-duration treatment option with better outcomes.